These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 21518728)

  • 1. Effective melanoma immunotherapy with interleukin-2 delivered by a novel polymeric nanoparticle.
    Yao H; Ng SS; Huo LF; Chow BK; Shen Z; Yang M; Sze J; Ko O; Li M; Yue A; Lu LW; Bian XW; Kung HF; Lin MC
    Mol Cancer Ther; 2011 Jun; 10(6):1082-92. PubMed ID: 21518728
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Functional characterization of a PEI-CyD-FA-coated adenovirus as delivery vector for gene therapy.
    Yao H; Chen SC; Shen Z; Huang YC; Zhu X; Wang XM; Jiang W; Wang ZF; Bian XW; Ling EA; Kung HF; Lin MC
    Curr Med Chem; 2013; 20(20):2601-8. PubMed ID: 23531212
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined delivery of a TGF-β inhibitor and an adenoviral vector expressing interleukin-12 potentiates cancer immunotherapy.
    Jiang J; Zhang Y; Peng K; Wang Q; Hong X; Li H; Fan G; Zhang Z; Gong T; Sun X
    Acta Biomater; 2017 Oct; 61():114-123. PubMed ID: 28483693
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vaccination using melanoma cells treated with p19arf and interferon beta gene transfer in a mouse model: a novel combination for cancer immunotherapy.
    Medrano RF; Catani JP; Ribeiro AH; Tomaz SL; Merkel CA; Costanzi-Strauss E; Strauss BE
    Cancer Immunol Immunother; 2016 Apr; 65(4):371-82. PubMed ID: 26887933
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ALKS 4230: a novel engineered IL-2 fusion protein with an improved cellular selectivity profile for cancer immunotherapy.
    Lopes JE; Fisher JL; Flick HL; Wang C; Sun L; Ernstoff MS; Alvarez JC; Losey HC
    J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32317293
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effective induction of therapeutic antitumor immunity by dendritic cells coexpressing interleukin-18 and tumor antigen.
    Xia D; Zheng S; Zhang W; He L; Wang Q; Pan J; Zhang L; Wang J; Cao X
    J Mol Med (Berl); 2003 Sep; 81(9):585-96. PubMed ID: 12937899
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhancing Dendritic Cell-based Immunotherapy with IL-2/Monoclonal Antibody Complexes for Control of Established Tumors.
    Kim MT; Richer MJ; Gross BP; Norian LA; Badovinac VP; Harty JT
    J Immunol; 2015 Nov; 195(9):4537-44. PubMed ID: 26408669
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Granulocyte-macrophage colony-stimulating factor and interleukin-2 fusion cDNA for cancer gene immunotherapy.
    Stagg J; Wu JH; Bouganim N; Galipeau J
    Cancer Res; 2004 Dec; 64(24):8795-9. PubMed ID: 15604233
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synergistic antitumor effects of CpG oligodeoxynucleotide and STAT3 inhibitory agent JSI-124 in a mouse melanoma tumor model.
    Molavi O; Ma Z; Hamdy S; Lai R; Lavasanifar A; Samuel J
    Immunol Cell Biol; 2008; 86(6):506-14. PubMed ID: 18392040
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IL-2 in vivo activities and antitumor efficacy enhanced by an anti-IL-2 mAb.
    Kamimura D; Sawa Y; Sato M; Agung E; Hirano T; Murakami M
    J Immunol; 2006 Jul; 177(1):306-14. PubMed ID: 16785526
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vivo antitumor activity of interleukin 21 mediated by natural killer cells.
    Wang G; Tschoi M; Spolski R; Lou Y; Ozaki K; Feng C; Kim G; Leonard WJ; Hwu P
    Cancer Res; 2003 Dec; 63(24):9016-22. PubMed ID: 14695220
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interleukin-18 gene transfer increases antitumor effects of suicide gene therapy through efficient induction of antitumor immunity.
    Ju DW; Yang Y; Tao Q; Song WG; He L; Chen G; Gu S; Ting CC; Cao X
    Gene Ther; 2000 Oct; 7(19):1672-9. PubMed ID: 11083476
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adenoviral production of interleukin-2 at the tumor site removes the need for systemic postconditioning in adoptive cell therapy.
    Santos JM; Havunen R; Siurala M; Cervera-Carrascon V; Tähtinen S; Sorsa S; Anttila M; Karell P; Kanerva A; Hemminki A
    Int J Cancer; 2017 Oct; 141(7):1458-1468. PubMed ID: 28614908
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intracranial paracrine interleukin-2 therapy stimulates prolonged antitumor immunity that extends outside the central nervous system.
    Ewend MG; Thompson RC; Anderson R; Sills AK; Staveley-O'Carroll K; Tyler BM; Hanes J; Brat D; Thomas M; Jaffee EM; Pardoll DM; Brem H
    J Immunother; 2000; 23(4):438-48. PubMed ID: 10916753
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Marrow stromal cells for interleukin-2 delivery in cancer immunotherapy.
    Stagg J; Lejeune L; Paquin A; Galipeau J
    Hum Gene Ther; 2004 Jun; 15(6):597-608. PubMed ID: 15212718
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Localized immunotherapy via liposome-anchored Anti-CD137 + IL-2 prevents lethal toxicity and elicits local and systemic antitumor immunity.
    Kwong B; Gai SA; Elkhader J; Wittrup KD; Irvine DJ
    Cancer Res; 2013 Mar; 73(5):1547-58. PubMed ID: 23436794
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sustained IL-2R signaling of limited duration by high-dose mIL-2/mCD25 fusion protein amplifies tumor-reactive CD8
    Hernandez R; Toomer KH; Põder J; Santos Savio A; Hsiung S; Malek TR
    Cancer Immunol Immunother; 2021 Apr; 70(4):909-921. PubMed ID: 33037893
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Significant antitumor effects obtained by autologous tumor cell vaccine engineered to secrete interleukin (IL)-12 and IL-18 by means of the EBV/lipoplex.
    Asada H; Kishida T; Hirai H; Satoh E; Ohashi S; Takeuchi M; Kubo T; Kita M; Iwakura Y; Imanishi J; Mazda O
    Mol Ther; 2002 May; 5(5 Pt 1):609-16. PubMed ID: 11991752
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of a novel IL-15 based protein with improved developability and efficacy for cancer immunotherapy.
    Hu Q; Ye X; Qu X; Cui D; Zhang L; Xu Z; Wan H; Zhang L; Tao W
    Sci Rep; 2018 May; 8(1):7675. PubMed ID: 29769573
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CCR5 Blockade Suppresses Melanoma Development Through Inhibition of IL-6-Stat3 Pathway via Upregulation of SOCS3.
    Tang Q; Jiang J; Liu J
    Inflammation; 2015 Dec; 38(6):2049-56. PubMed ID: 26047948
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.